Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cibus, Inc.
Report date March 01, 2023 · Filed June 02, 2023
Section 16 reporting ended · disclosed 2023-06-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right-to-Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.55 · Expires 2030-08-04 | Direct | 0 |
Reported balance
After 2023-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-01 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. |
| Stock Option (Right-to-Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.55 · Expires 2030-08-04 | Direct | 5,000 |
Reported balance
After 2023-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-01 · Grant · Acquired 5,000 · Balance 5,000 F1: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. |
| Stock Option (Right-to-Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.22 · Expires 2031-05-27 | Direct | 0 |
Reported balance
After 2023-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-01 · Disposition to issuer · Disposed 10,291 · Balance 0 F1: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. |
| Stock Option (Right-to-Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.22 · Expires 2031-05-27 | Direct | 10,291 |
Reported balance
After 2023-03-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-03-01 · Grant · Acquired 10,291 · Balance 10,291 F1: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. |
| Stock Option (Right-to-Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2032-06-13 | Direct | 0 |
Reported balance
After 2023-03-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-01 · Disposition to issuer · Disposed 32,700 · Balance 0 F1: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. |
| Stock Option (Right-to-Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2032-06-13 | Direct | 32,700 |
Reported balance
After 2023-03-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-01 · Grant · Acquired 32,700 · Balance 32,700 F1: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2023 Filed Jun 2, 2023 00:11 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right-to-Buy) · Derivative | 32,700 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0001615594-23-000041 · primary_doc.xml · derivative · entry 6 Dumont Philippe · CIK 0001712186 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,700 Underlying: Common Stock · 32,700 shares Expires 2032-06-13 F1 · kind: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. F1 · price: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. F1 · derivative.exercise_date: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. Read SEC document |
| March 01, 2023 Filed Jun 2, 2023 00:11 UTC | Cibus, Inc. CLXT · Entity 6658 | Disposition to issuerStock Option (Right-to-Buy) · Derivative | 32,700 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0001615594-23-000041 · primary_doc.xml · derivative · entry 5 Dumont Philippe · CIK 0001712186 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,700 shares Expires 2032-06-13 F1 · kind: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. F1 · price: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. F1 · derivative.exercise_date: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. Read SEC document |
| March 01, 2023 Filed Jun 2, 2023 00:11 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right-to-Buy) · Derivative | 10,291 | Not disclosed Strike: $4.22 | Not disclosed |
DisclosureSEC source: 0001615594-23-000041 · primary_doc.xml · derivative · entry 4 Dumont Philippe · CIK 0001712186 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,291 Underlying: Common Stock · 10,291 shares Expires 2031-05-27 F1 · kind: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. F1 · price: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. F1 · derivative.exercise_date: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. Read SEC document |
| March 01, 2023 Filed Jun 2, 2023 00:11 UTC | Cibus, Inc. CLXT · Entity 6658 | Disposition to issuerStock Option (Right-to-Buy) · Derivative | 10,291 | Not disclosed Strike: $4.22 | Not disclosed |
DisclosureSEC source: 0001615594-23-000041 · primary_doc.xml · derivative · entry 3 Dumont Philippe · CIK 0001712186 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,291 shares Expires 2031-05-27 F1 · kind: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. F1 · price: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. F1 · derivative.exercise_date: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. Read SEC document |
| March 01, 2023 Filed Jun 2, 2023 00:11 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right-to-Buy) · Derivative | 5,000 | Not disclosed Strike: $4.55 | Not disclosed |
DisclosureSEC source: 0001615594-23-000041 · primary_doc.xml · derivative · entry 2 Dumont Philippe · CIK 0001712186 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2030-08-04 F1 · kind: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. F1 · price: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. F1 · derivative.exercise_date: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. Read SEC document |
| March 01, 2023 Filed Jun 2, 2023 00:11 UTC | Cibus, Inc. CLXT · Entity 6658 | Disposition to issuerStock Option (Right-to-Buy) · Derivative | 5,000 | Not disclosed Strike: $4.55 | Not disclosed |
DisclosureSEC source: 0001615594-23-000041 · primary_doc.xml · derivative · entry 1 Dumont Philippe · CIK 0001712186 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2030-08-04 F1 · kind: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. F1 · price: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. F1 · derivative.exercise_date: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 20:13 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right-to-Buy) · Derivative | 32,700 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001615594-22-000036 · primary_doc.xml · derivative · entry 2 Dumont Philippe · CIK 0001712186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,700 Underlying: Common Stock · 32,700 shares Expires 2032-06-13 F1 · derivative.exercise_date: Option vests in full on the first anniversary of the date of the grant. Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 21:24 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right-to-Buy) · Derivative | 10,291 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0001615594-21-000063 · primary_doc.xml · derivative · entry 2 Dumont Philippe · CIK 0001712186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,291 Underlying: Common Stock · 10,291 shares Expires 2031-05-27 F2 · derivative.exercise_date: The option vests in full on 5/27/2022. Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 21:24 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantCommon Stock | 7,204 | $0.00 | $0.00 |
DisclosureSEC source: 0001615594-21-000063 · primary_doc.xml · nonDerivative · entry 1 Dumont Philippe · CIK 0001712186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,614 F1 · shares: The Restricted Stock Units vest in full on 5/27/2022. Read SEC document |
| September 10, 2020 Filed Sep 11, 2020 21:06 UTC | Cibus, Inc. CLXT · Entity 6658 | PurchaseCommon Stock | 3,000 | $5.91 | $17,728.80 |
DisclosureSEC source: 0001615594-20-000065 · primary_doc.xml · nonDerivative · entry 1 Dumont Philippe · CIK 0001712186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,290 Read SEC document |
| August 14, 2020 Filed Aug 21, 2020 21:16 UTC | Cibus, Inc. CLXT · Entity 6658 | PurchaseCommon Stock | 2,000 | $7.49 | $14,970.40 |
DisclosureSEC source: 0001615594-20-000061 · primary_doc.xml · nonDerivative · entry 3 Dumont Philippe · CIK 0001712186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,290 Read SEC document |
| August 04, 2020 Filed Aug 7, 2020 21:50 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right-to-Buy) · Derivative | 5,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001615594-20-000048 · primary_doc.xml · derivative · entry 2 Dumont Philippe · CIK 0001712186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2030-08-04 F1 · derivative.exercise_date: The option vests as to 1/3 of the shares on each of the first three anniversaries of the date of the grant. Read SEC document |
| July 02, 2020 Filed Aug 21, 2020 21:16 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 236 | $4.70 | $1,109.20 |
DisclosureSEC source: 0001615594-20-000061 · primary_doc.xml · nonDerivative · entry 2 Dumont Philippe · CIK 0001712186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,290 F1 · shares: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on June 13, 2019. Read SEC document |
| April 02, 2020 Filed Aug 21, 2020 21:16 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 236 | $2.87 | $677.32 |
DisclosureSEC source: 0001615594-20-000061 · primary_doc.xml · nonDerivative · entry 1 Dumont Philippe · CIK 0001712186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,526 F1 · shares: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on June 13, 2019. Read SEC document |
| January 03, 2020 Filed Jan 8, 2020 00:37 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 236 | $7.60 | $1,793.60 |
DisclosureSEC source: 0001615594-20-000002 · primary_doc.xml · nonDerivative · entry 1 Dumont Philippe · CIK 0001712186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,762 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on June 13, 2019. Read SEC document |
| October 02, 2019 Filed Oct 3, 2019 17:46 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 236 | $4.96 | $1,170.56 |
DisclosureSEC source: 0001615594-19-000036 · primary_doc.xml · nonDerivative · entry 1 Dumont Philippe · CIK 0001712186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,998 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on June 13, 2019. Read SEC document |
| July 18, 2019 Filed Jul 22, 2019 15:17 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 706 | $10.00 | $7,060.00 |
DisclosureSEC source: 0001615594-19-000029 · primary_doc.xml · nonDerivative · entry 1 Dumont Philippe · CIK 0001712186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,234 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on November 20, 2017. Read SEC document |
| July 18, 2019 Filed Jun 1, 2021 21:19 UTC Amendment | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 706 | $10.00 | $7,060.00 |
DisclosureSEC source: 0001615594-21-000062 · primary_doc.xml · nonDerivative · entry 1 Dumont Philippe · CIK 0001712186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,354 F1 · shares: The sale reported on the Form 4 originally filed was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on November 30, 2017. F2 · balance_after: The amount of securities beneficially owned by reporting person following the transaction was incorrectly stated. Read SEC document |
| May 06, 2019 Filed May 9, 2019 00:40 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $15.59 | $0.00 |
DisclosureSEC source: 0001127602-19-017807 · form4.xml · derivative · entry 1 Dumont Philippe · CIK 0001712186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-05-06 F1 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on May 6, 2019 and vests 15% on May 6, 2020 and 15% on May 6, 2021, with the remainder vesting quarterly (commencing with the third fiscal quarter of 2021) in equal installments over 42 months. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 21:09 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 1,117 | $12.00 | $13,404.00 |
DisclosureSEC source: 0001127602-19-001635 · form4.xml · nonDerivative · entry 1 Dumont Philippe · CIK 0001712186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,060 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017. F2 · balance_after: Includes 16,660 RSUs with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 2,940 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| October 05, 2018 Filed Oct 9, 2018 20:14 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 1,117 | $14.11 | $15,765.23 |
DisclosureSEC source: 0001127602-18-029802 · form4.xml · nonDerivative · entry 1 Dumont Philippe · CIK 0001712186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,177 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017. F2 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $14.08 to $14.19, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4 F3 · balance_after: Includes 16,660 RSUs with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 2,940 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| June 15, 2018 Filed Jun 15, 2018 22:15 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 706 | $19.49 | $13,759.94 |
DisclosureSEC source: 0001127602-18-021066 · form4.xml · nonDerivative · entry 1 Dumont Philippe · CIK 0001712186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,294 F1 · shares: Represents the sale of shares to Cellectis, S.A. pursuant to a Share Purchase Agreement, dated June 13, 2018, among the reporting person, Cellectis, S.A. and the issuer to cover tax obligations of the reporting person in connection with the vesting on June 14, 2018 of restricted stock units ("RSUs") granted by the issuer to the reporting person. F2 · balance_after: Includes 16,660 RSUs with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 2,940 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| July 25, 2017 Filed Jul 28, 2017 01:52 UTC | Cibus, Inc. CLXT · Entity 6658 | PurchaseCommon Stock | 400 | $8.00 | $3,200.00 |
DisclosureSEC source: 0000950103-17-007203 · dp78782_4-dumont.xml · nonDerivative · entry 2 Dumont Philippe · CIK 0001712186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F2 · shares: Represents purchase of shares in the Company's directed share program in connection with the Company's initial public offering. Read SEC document |
| June 14, 2017 Filed Jul 28, 2017 01:52 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right to buy) · Derivative | 29,400 | $0.00 Strike: $13.29 | $0.00 |
DisclosureSEC source: 0000950103-17-007203 · dp78782_4-dumont.xml · derivative · entry 3 Dumont Philippe · CIK 0001712186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,400 Underlying: Common Stock · 29,400 shares Expires 2027-06-14 F3 · derivative.exercise_date: The stock option to purchase Company common stock vests 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| June 14, 2017 Filed Jul 28, 2017 01:52 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantRestricted Stock Unit | 19,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-17-007203 · dp78782_4-dumont.xml · nonDerivative · entry 1 Dumont Philippe · CIK 0001712186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,600 F1 · shares: Restricted stock units with respect to Calyxt, Inc. (the "Company") common stock vest 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.